[6-(1-piperidinylmethyl)-7,8-dihydro-2-naphthalenyl]amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: [6-(1-piperidinylmethyl)-7,8-dihydro-2-naphthalenyl]amine
• 英文别名: 6-(1-piperidinylmethyl)-7,8-dihydro-2-naphthalenamine；6-(Piperidin-1-ylmethyl)-7,8-dihydronaphthalen-2-amine
• 化学式: C₁₆H₂₂N₂
• 分子量: 242.364
• InChiKey: KRPWZRDMUUEQES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 5-(4-chlorophenyl)-3-{[(1E)-(dimethylamino)methylidene]amino}-2-thiophenecarboxylate 、 [6-(1-piperidinylmethyl)-7,8-dihydro-2-naphthalenyl]amine 以 苯酚 为溶剂， 反应 1.5h， 生成 6-(4-chlorophenyl)-3-[6-(1-piperidinylmethyl)-7,8-dihydro-2-naphthalenyl]thieno[3,2-d]pyrimidin-4(3H)-one
  参考文献：
  名称：

  6-(4-Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-Based Melanin-Concentrating Hormone Receptor 1 Antagonist

  摘要：

  Genetic manipulation studies in mice at both the MCH receptor 1 (MCHR1) as well as the MCH peptide levels have implicated MCHR1 as a key player in energy homeostasis. The phenotype exhibited by these studies, that is, increased metabolic rate, resistance to high fat diet, and subsequent weight loss, has spurred considerable efforts to develop antagonists of MCHR1. In continuation of efforts directed toward this goal, the present work capitalizes on the putative binding mode of an MCH antagonist, resulting in the identification of several novel chemotypes that are potent and selective MCHR1 antagonists. In addition, the favorable pharmacokinetics of representative examples has allowed for the evaluation of an MCHR1 antagonist in a high fat diet-induced obese rodent model of obesity. The tolerability of the right-hand side of the template for diverse chemotypes accompanied by favorable effects on weight loss enhances the attractiveness of this template in the pursuit toward development of effective anti-obesity agents.

  DOI：

  10.1021/jm060814b

文献信息

• Melanin concentrating hormone antagonist
  申请人：Kato Kaneyoshi

  公开号：US20070173498A1

  公开（公告）日：2007-07-26

  A melanin-concentrating hormone antagonist which comprises a compound of the formula: wherein Ar 1 is a cyclic group which may have substituents; X is a spacer having a main chain of 1 to 6 atoms; Y is a bond or a spacer having a main chain of 1 to 6 atoms; Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents; R 1 and R 2 are independently hydrogen atom or a hydrocarbon group which may have substituents; R 1 and R 2 , together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R 2 may form a spiro ring together with Ar; or R 2 , together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof; which is useful as an agent for preventing or treating obesity, etc.

  一种黑色素浓集激素拮抗剂，包括一个化合物，其化学式为：其中Ar1是一个环状基团，可能具有取代基；X是一个具有1到6个原子主链的间隔物；Y是一条键或具有1到6个原子主链的间隔物；Ar是一个单环芳香环，可以与一个4到8个成员的非芳香环融合，并且可能有进一步的取代基；R1和R2分别是氢原子或一个可能具有取代基的碳氢基团；R1和R2连同相邻的氮原子可以形成一个含氮杂环，该杂环可能具有取代基；R2可以与Ar一起形成一个螺环；或者R2连同相邻的氮原子和Y可以形成一个含氮杂环，该杂环可能具有取代基；或其盐；用作预防或治疗肥胖等的药剂。
• MELANIN CONCENTRATING HORMONE ANTAGONIST
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1218336A2

  公开（公告）日：2002-07-03
• US7115750B1
  申请人：——

  公开号：US7115750B1

  公开（公告）日：2006-10-03
• [EN] MELANIN CONCENTRATING HORMONE ANTAGONIST<br/>[FR] ANTAGONISTE DE L'HORMONE DE CONCENTRATION DE LA MELANINE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2001021577A2

  公开（公告）日：2001-03-29

  A melanin-concentrating hormone antagonist which comprises a compound of formula (I) wherein Ar1 is a cyclic group which may have substituents; X is a spacer having a main chain of 1 to 6 atoms; Y is a bond or a spacer having a main chain of 1 to 6 atoms; Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents; R?1 and R2¿ are independently hydrogen atom or a hydrocarbon group which may have substituents; R?1 and R2¿, together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R2 may form a spiro ring together with Ar; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof; which is useful as an agent for preventing or treating obesity, etc.
• 6-(4-Chlorophenyl)-3-substituted-thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one-Based Melanin-Concentrating Hormone Receptor 1 Antagonist
  作者：Francis X. Tavares、Kamal A. Al-Barazanji、Michael J. Bishop、Christy S. Britt、David L. Carlton、Joel P. Cooper、Paul L. Feldman、Dulce M. Garrido、Aaron S. Goetz、Mary K. Grizzle、Donald L. Hertzog、Diane M. Ignar、Daniel G. Lang、Maggie S. McIntyre、Ronda J. Ott、Andrew J. Peat、Hui-Qiang Zhou

  DOI：10.1021/jm060814b

  日期：2006.11.30

  Genetic manipulation studies in mice at both the MCH receptor 1 (MCHR1) as well as the MCH peptide levels have implicated MCHR1 as a key player in energy homeostasis. The phenotype exhibited by these studies, that is, increased metabolic rate, resistance to high fat diet, and subsequent weight loss, has spurred considerable efforts to develop antagonists of MCHR1. In continuation of efforts directed toward this goal, the present work capitalizes on the putative binding mode of an MCH antagonist, resulting in the identification of several novel chemotypes that are potent and selective MCHR1 antagonists. In addition, the favorable pharmacokinetics of representative examples has allowed for the evaluation of an MCHR1 antagonist in a high fat diet-induced obese rodent model of obesity. The tolerability of the right-hand side of the template for diverse chemotypes accompanied by favorable effects on weight loss enhances the attractiveness of this template in the pursuit toward development of effective anti-obesity agents.